We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Samuel
Resendez
samuel.resendez@nhs.net
Janet
Piggott
janet.piggott@nihr.ac.uk
Dr
ian
wilkinson
ibw20@cam.ac.uk
Spoorthy
Kulkarni
sp948@cam.ac.uk
Spoorthy
Kulkarni
sp948@cam.ac.uk
Hypertensive diseasesDisorders of other endocrine glands
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Primary aldosteronism is considered a common secondary cause of hypertension and it occurs due to the unregulated secretion of a hormone called aldosterone which in turn leads to a rise in blood pressure. Approximately,5-10% of patients presenting with hypertension,may have underlying primary aldosteronism. The diagnosis relies on the results of screening tests which is a randomly taken blood test sample. It is possible that the current screening strategy may be not adequately robust enough to rule out primary aldosteronism in all patients with hypertension and this study aims to check if an available alternative screening test may be comparatively better in subsets of patients. Thus,this pilot study aims to first ensure it is feasible to undertake the testing and compare the currently used screening test for primary aldosteronism namely the plasma aldosterone renin ratio (measured in blood samples) with 24-hour urine aldosterone measurement undertaken in a routinely collected 24-hour urine sample which is undertaken to assess water and salt balance in specialist hypertension clinics. 24-hour urine aldosterone is a test normally undertaken as part of a confirmatory test called an oral salt loading test in hypertensive patients suspected of primary aldosteronism,however not at the screening stage. All procedures described in the study are part of the standard of care,with the only additional procedure being an assessment of 24-hour urine aldosterone in the routinely collected 24-hour urine electrolytes test.
Patients with clinical suspicion of primary aldosterone (typically patients with medication-resistant hypertension and/or hypertension with electrolyte disturbances) and patients without clinical suspicion will be recruited across 4 specialist hypertension centers in the UK over a period of 1 year. The results of this study will be used to plan and design a larger study and subsequently to compare the two tests in a wider population.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cross-sectional;
You can take part if:
You may not be able to take part if:
Severe hypertension (sustained blood pressure of >200/110 mmHg) or a history of known secondary hypertension other than primary aldosteronism,pregnant and/or breastfeeding individuals. Individuals who have contraindications to confirmatory testing for primary aldosteronism with a saline infusion or oral salt loading test as per standard clinical criteria such as known clinical diagnosis of heart failure,and/or chronic kidney disease stage 3b,4,and 5 and/or dialysis. Patients who are currently pregnant and/or breastfeeding. Participants with any medical condition deemed unsuitable by an investigator for participation in the study where the risk versus benefit of primary aldosteronism is high will be excluded. Those who do not provide informed consent will be obviously excluded.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Janet
Piggott
janet.piggott@nihr.ac.uk
Spoorthy
Kulkarni
sp948@cam.ac.uk
Samuel
Resendez
samuel.resendez@nhs.net
Dr
ian
wilkinson
ibw20@cam.ac.uk
Spoorthy
Kulkarni
sp948@cam.ac.uk
The study is sponsored by CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST and funded by BRITISH HEART FOUNDATION .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 57775
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
